Elucigene Diagnostics, Lifecodexx Partner

Elucigene Diagnostics and LifeCodexx AG announced that they have partnered with the aim of providing access for UK and Irish patients to LifeCodexx’ proprietary PrenaTest® NIPT technology.

PrenaTest® was Europe’s first non-invasive prenatal test (NIPT), significantly enhancing prenatal trisomy screening sensitivity, whilst drastically reducing invasive procedure linked pregnancy loss occurrence. The test is performed within Germany in strict conformity with the highest quality standards as per the European Directive on In-vitro Diagnostic Medical Devices. Currently, every 30 minutes a pregnant woman opts for PrenaTest® being a leading NIPT across Europe and the Middle East.

Dr. Mark Street-Docherty, Commercial Manager of Elucigene Diagnostics says “We are delighted to be able to offer pregnant women across the UK access to leading NIPT technology, ensuring safe and accurate screening for the most common chromosomal trisomies. This service complements our continued support for prenatal testing accuracy, alongside our leading QST*R diagnostic prenatal range”.

“We are very pleased to add Elucigene Diagnostics to our group of partners with their long standing expertise in the field of prenatal diagnostic in the U.K but also elsewhere,” added Dr. Michael Lutz, CEO of LifeCodexx. “With this new partnership, our high quality PrenaTest® is now available in more than 40 countries throughout Europe and the Middle East.”